Drug Trial Radar · NCT00133003
Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
Last checked: Nov 20, 2026Latest source record: Apr 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,022
Actual
Start
Mar 2003
Primary completion
Jan 2006
Study completion Jan 2006
Sponsor
- Lead sponsor
- Deutsches Herzzentrum MuenchenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Technical University of Munich
- First posted
- Aug 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.
Conditions
- Coronary Disease
- Angina, Unstable
Interventions
AbciximabDrug
0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
PlaceboDrug
Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite rate of death, myocardial infarction, and urgent target vessel revascularization within 30 daysTime frame: 30 days
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil
Herz-Zentrum
Bad Krozingen, Germany
Deutsches Herzzentrum Muenchen
Munich, Germany
First Medizinische Klinik, Klinikum rechts der Isar
Munich, Germany
St. Antonius Ziekenhuis Hospital
Nieuwegein, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.